For drug developers and academic researchers, the bottleneck is often not the AI model, but the data that feeds it. The promise of machine learning in biology has been tempered by the messy, expensive, and often destructive reality of preparing biological samples. A startup emerging from Fremont, California, is betting that a physics-based sensor can cut through that complexity, turning a drop of liquid into a high-dimensional digital signature ready for algorithmic analysis. Probius, founded in 2015, is developing a smartphone-sized device that uses what it calls Quantum Electrochemical Spectroscopy (QES) to measure molecular vibrations in proteins, metabolites, and other small molecules [UCeed, ~2022-2023]. The output is not a traditional chemical assay but a 40-dimensional 'digital twin' of the specimen, stored in the cloud where it can be re-analyzed indefinitely [UCeed, ~2022-2023].
The hardware wedge into AI's data problem
The core of Probius's bet is a piece of hardware, a deliberate choice in a software-dominated field. The company's QES technology is designed to require minimal sample preparation, working directly on biological aliquots without added reagents [Probius LinkedIn, retrieved 2026]. This positions the device as a potential wedge into laboratories where speed, cost, and sample preservation are critical. The initial target customers are biomedical researchers and pharmaceutical companies looking to shift from traditional, batch-based analytical chemistry to a more continuous, data-centric workflow [BusinessWire, Sep 2022].
A founding team built on sensor physics
The technical ambition is matched by a founding team with deep roots in sensor fabrication and nanotechnology. CEO Emmanuel P. Quevy holds a PhD and brings expertise in advanced sensor commercialization [Probius.bio]. He is joined by co-founder Roger T. Howe, the former director of the Stanford Nanofabrication Facility and a noted expert in microelectromechanical systems (MEMS) [ECE Florida News, Jan 2024]. The third co-founder, Chaitanya Gupta, serves as CTO with a background in engineering research at Stanford University [The Org, retrieved 2026]. This hardware-heavy foundation was bolstered in 2022 with strategic commercial hires: John Baldoni, PhD, as Chief Scientific Officer and Juan C. Cuevas, PhD, as SVP of Marketing and Business Development, both bringing biopharma industry experience [BusinessWire, Sep 2022].
| Role | Name | Key Background |
|---|---|---|
| Co-Founder & CEO | Emmanuel P. Quevy, PhD | Advanced sensor products and technology commercialization [Probius.bio]. |
| Co-Founder | Roger T. Howe, PhD | Former Director, Stanford Nanofabrication Facility; MEMS authority [ECE Florida News, Jan 2024]. |
| Co-Founder & CTO | Chaitanya Gupta, PhD | Prior Engineering Research Associate, Stanford University [The Org, retrieved 2026]. |
| Chief Scientific Officer | John Baldoni, PhD | Hired September 2022; biopharma R&D experience [BusinessWire, Sep 2022]. |
| SVP Marketing & Business Dev. | Juan C. Cuevas, PhD | Hired September 2022; biopharma commercial experience [BusinessWire, Sep 2022]. |
Early signals and a strategic partnership
Public traction data is scarce, a common challenge for deep-tech hardware companies in development. Probius has secured backing from university venture fund UCeed, Heuristic Capital, and Zoic Capital [UCeed, ~2022-2023]. Its most concrete public move since a 2022 launch announcement is a strategic collaboration with SaponiQx and synthetic biology giant Ginkgo Bioworks, focused on using its quantum molecular spectroscopy for AI-driven vaccine adjuvant discovery [Indian Pharma Post].
Navigating a high-risk, high-reward path
The vision is compelling, but the path is lined with technical and commercial hurdles. The technology itself must prove it can deliver consistent, biologically relevant signatures across the chaotic diversity of real-world samples. Furthermore, the company must navigate the adoption cycle for research hardware, which is typically long and requires demonstrating clear superiority over entrenched methods like mass spectrometry or nuclear magnetic resonance (NMR) imaging.
- Technical validation. The fundamental claim awaits peer-reviewed publication and independent replication.
- Commercial adoption. Selling capital equipment into academic and pharma labs is a grind.
- Regulatory context. While the initial research use case does not require FDA clearance, any eventual diagnostic application would.
The next twelve months for a quiet contender
Probius operates with a notable lack of fanfare for a company founded nearly a decade ago. The key milestones to watch for will be less about fundraising and more about tangible proof points in the coming year. Publication of validation data in a reputable journal would be a major signal. The expansion of the Ginkgo collaboration or the announcement of additional pilot partners would demonstrate commercial momentum.